Vaxart, Inc.
170 Harbor Way
Suite 300
South San Francisco
CA
94080
United States
Tel: 650-550-3500
Website: http://www.vaxart.com/
Email: hr@vaxart.com
About Vaxart, Inc.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury.
Vaxart has demonstrated that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication.
Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. All intellectual property is fully owned by Vaxart, without any encumbrances.
Stock Symbol: VXRT
Stock Exchange: NASDAQ
84 articles with Vaxart, Inc.
-
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
11/22/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.
-
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
11/8/2022
Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the third quarter of 2022, during which the Company made significant progress on its oral vaccine candidates.
-
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
10/20/2022
Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022.
-
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
10/10/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022.
-
Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
-
Biopharma and life sciences companies, such as Seraxis, Verily and Vaxart, tap new members to bolster their leadership teams in roles like CMO, CTO, CCO, and more.
-
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
9/1/2022
Vaxart, Inc. reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S.
-
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
8/31/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022.
-
Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer
8/31/2022
Vaxart, Inc. announced that it has named Ray Stapleton, Ph.D., as its Chief Technology Officer, effective immediately.
-
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
8/25/2022
Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022.
-
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8/8/2022
In its business update today for the second quarter of 2022, Vaxart, Inc. (NASDAQ: VXRT) said it has begun working on vaccine candidate constructs that directly target new omicron variants of concern and is preparing to release top-line data in the third quarter of 2022 from its Phase II COVID-19 testing of a Wuhan strain vaccine construct.
-
Vaxart Appoints W. Mark Watson to its Board of Directors
8/8/2022
Vaxart, Inc. (NASDAQ: VXRT) today announced that W. Mark Watson was appointed to the Company’s Board of Directors, effective August 4, 2022.
-
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
8/5/2022
Vaxart, Inc. announced that at its reconvened Annual Meeting of Stockholders on August 4, its stockholders had voted to approve Proposals 2, 3 and 4.
-
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
7/28/2022
Vaxart, Inc. announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after the market close on Monday, August 8, 2022.
-
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
7/27/2022
Vaxart, Inc. (Nasdaq: VXRT) today urged its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so and encouraged them to vote yes on all Proxy Proposals, including Proxy Proposal #2.
-
Researchers evaluate just how well therapeutic antibodies and antivirals work against Omicron, Vaxart's oral vaccine shows early promise and hypertension doubles the risk of hospitalization.
-
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
7/20/2022
Vaxart (NASDAQ: VXRT) today reported additional phase 1 clinical data published on medRixv.org, indicating that its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against SARS-CoV-2 the virus that causes COVID-19, and all tested coronaviruses.
-
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
7/14/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine development program at the International Congress of Mucosal Immunology 2022, which is being held in Seattle July 16 to 20, 2022.
-
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
7/1/2022
Vaxart, Inc. urges its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so.
-
Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model
6/30/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan plc (AIM: ORPH) under which hVIVO will conduct a characterization study and, if successful, develop a human challenge model based on the Omicron variant of SARS-CoV-2.